UY30878A1 - La sal tosilato de trans-n-etil-3-fluoro-3-[3-fluoro-4 (pirrolidin-1-ilmetil)fenil] ciclobutanocarboxamida, composición farmacéutica conteniéndola y aplicaciones - Google Patents
La sal tosilato de trans-n-etil-3-fluoro-3-[3-fluoro-4 (pirrolidin-1-ilmetil)fenil] ciclobutanocarboxamida, composición farmacéutica conteniéndola y aplicacionesInfo
- Publication number
- UY30878A1 UY30878A1 UY030878A UY30878A UY30878A1 UY 30878 A1 UY30878 A1 UY 30878A1 UY 030878 A UY030878 A UY 030878A UY 30878 A UY30878 A UY 30878A UY 30878 A1 UY30878 A1 UY 30878A1
- Authority
- UY
- Uruguay
- Prior art keywords
- fluoro
- disorders
- trans
- phenyl
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Sal tosilato de trans-N-etil-3-fluoro-3-[3-fluoro-4-(pirrolidin-1-ilmetil)fenil]ciclobutanocarboxamida (1): a solvatos, a polimorfos, a composiciones farmacéuticas de la misma y a un procedimiento de tratamiento de depresión, trastornos del ánimo, esquizofrenia,trastorno de ansiedad, trastonos cognitovos, enfermedad de Alzheimer, trastornos de déficit de atención (TDA), trastorno de déficit de atención con hiperactividad (TDAH), trastonos psicóticos, trastornos del sueno, obesidad, vértigo, epilepsia, cinetosis, enfermedades respiratorias, alergia, respuestas de las vías aéreas inducidas por alergia, rinitis alérgica, congestión nasal, congestión alérgica, congestión, hipotensión, enfermedad cardiovascular, enfermedades del tracto GI, hiper-e hipomotilidad y secreción ácida del tracto gastrointestinal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88593107P | 2007-01-22 | 2007-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY30878A1 true UY30878A1 (es) | 2009-08-31 |
Family
ID=39277093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY030878A UY30878A1 (es) | 2007-01-22 | 2008-01-21 | La sal tosilato de trans-n-etil-3-fluoro-3-[3-fluoro-4 (pirrolidin-1-ilmetil)fenil] ciclobutanocarboxamida, composición farmacéutica conteniéndola y aplicaciones |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8314139B2 (es) |
| EP (1) | EP2124933B1 (es) |
| JP (1) | JP4585610B2 (es) |
| KR (1) | KR101108109B1 (es) |
| CN (1) | CN101631545B (es) |
| AR (1) | AR064963A1 (es) |
| AU (1) | AU2008208653B2 (es) |
| BR (1) | BRPI0806473A2 (es) |
| CA (1) | CA2676456C (es) |
| CL (1) | CL2008000180A1 (es) |
| DK (1) | DK2124933T3 (es) |
| ES (1) | ES2395744T3 (es) |
| HK (1) | HK1137660A1 (es) |
| IL (1) | IL199587A (es) |
| MX (1) | MX2009007782A (es) |
| NZ (1) | NZ577951A (es) |
| PE (1) | PE20081690A1 (es) |
| PL (1) | PL2124933T3 (es) |
| PT (1) | PT2124933E (es) |
| RU (1) | RU2430099C2 (es) |
| SI (1) | SI2124933T1 (es) |
| TW (1) | TWI358294B (es) |
| UY (1) | UY30878A1 (es) |
| WO (1) | WO2008090429A1 (es) |
| ZA (1) | ZA200905827B (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8158673B2 (en) * | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| UA98772C2 (ru) * | 2006-06-23 | 2012-06-25 | Эбботт Леборетриз | Производные циклопропиламина как модуляторы н3-гистаминового рецептора |
| US9108948B2 (en) * | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| MX2010006162A (es) * | 2007-12-07 | 2010-06-25 | Pfizer | Sal tosilato de una trans-n-isobutil-3-fluoro-3-[3-fluoro-4-(pirro lidin-1-il-metil)fenil]ciclobutanocarboxamida. |
| US20090221648A1 (en) * | 2007-12-21 | 2009-09-03 | Abbott Laboratories | Compositions for treatment of cognitive disorders |
| US8383657B2 (en) * | 2007-12-21 | 2013-02-26 | Abbott Laboratories | Thiazolylidine urea and amide derivatives and methods of use thereof |
| US9186353B2 (en) * | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
| WO2012037258A1 (en) | 2010-09-16 | 2012-03-22 | Abbott Laboratories | Processes for preparing 1,2-substituted cyclopropyl derivatives |
| EP2691393B1 (en) | 2011-03-31 | 2016-09-14 | Pfizer Inc | Novel bicyclic pyridinones |
| WO2012172449A1 (en) | 2011-06-13 | 2012-12-20 | Pfizer Inc. | Lactams as beta secretase inhibitors |
| EP2751116B1 (en) | 2011-08-31 | 2016-10-12 | Pfizer Inc | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds |
| ES2426539B1 (es) * | 2012-04-18 | 2014-09-09 | Dr Healthcare España, S. L. | Uso de la diaminooxidasa para el tratamiento o la prevención del trastorno por deficit de atencion con hiperactividad (adhd) |
| CA2872154C (en) | 2012-05-04 | 2016-08-23 | Pfizer Inc. | Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds as inhibitors of app, bace1 and bace2 |
| JP6189948B2 (ja) | 2012-06-29 | 2017-08-30 | ファイザー・インク | ＬＲＲＫ２阻害薬としての新規な４−（置換アミノ）−７Ｈ−ピロロ［２，３−ｄ］ピリミジン |
| EP2897964A1 (en) | 2012-09-20 | 2015-07-29 | Pfizer Inc. | Alkyl-substituted hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| CN103113405B (zh) * | 2012-10-17 | 2016-03-02 | 上海日馨生物科技有限公司 | 苯磷硫胺多晶型体、制备方法及其应用 |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| WO2014091352A1 (en) | 2012-12-11 | 2014-06-19 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
| JP6162820B2 (ja) | 2012-12-19 | 2017-07-12 | ファイザー・インク | 炭素環式および複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物 |
| CA2897678A1 (en) | 2013-02-13 | 2014-08-21 | Pfizer Inc. | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| CN105121439A (zh) | 2013-02-19 | 2015-12-02 | 辉瑞公司 | 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物 |
| EP3052495B1 (en) | 2013-10-04 | 2019-06-26 | Pfizer Inc | Novel bicyclic pyridinones as gamma-secretase modulators |
| CA2933767C (en) | 2013-12-17 | 2018-11-06 | Pfizer Inc. | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| CR20160454A (es) | 2014-04-01 | 2016-12-06 | Pfizer | CROMENO Y 1,1 a,2,7b—TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS |
| PE20170327A1 (es) | 2014-04-10 | 2017-04-21 | Pfizer | 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4d] [1,3] TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS |
| JP6713982B2 (ja) | 2014-07-24 | 2020-06-24 | ファイザー・インク | ピラゾロピリミジン化合物 |
| PE20170295A1 (es) | 2014-08-06 | 2017-03-30 | Pfizer | Compuestos de imidazopiridazina |
| EP3253755B1 (en) | 2015-02-03 | 2020-08-26 | Pfizer Inc | Novel cyclopropabenzofuranyl pyridopyrazinediones |
| CR20170572A (es) | 2015-06-17 | 2018-03-20 | Pfizer | Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa |
| KR102161364B1 (ko) | 2015-09-14 | 2020-09-29 | 화이자 인코포레이티드 | LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체 |
| JP2018531923A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド |
| EP3353182A1 (en) | 2015-09-24 | 2018-08-01 | Pfizer Inc | Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors |
| WO2017051294A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors |
| PL3419979T3 (pl) | 2016-02-23 | 2020-06-29 | Pfizer Inc. | Związki 6,7-dihydro-5h-pirazolo[5,1-b][1,3]oksazyno-2- karboksyamidowe |
| JP7046018B2 (ja) | 2016-07-01 | 2022-04-01 | ファイザー・インク | 神経性疾患および神経変性疾患を処置するための５，７－ジヒドロピロロピリジン誘導体 |
| EP3592741B1 (en) | 2017-03-10 | 2023-02-15 | Pfizer Inc. | Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors |
| AU2018230109B2 (en) | 2017-03-10 | 2022-05-12 | Pfizer Inc. | Cyclic substituted imidazo[4,5-c]quinoline derivatives |
| WO2018226992A1 (en) | 2017-06-07 | 2018-12-13 | Adrx, Inc. | Tau aggregation inhibitors |
| ES2937236T3 (es) | 2017-06-22 | 2023-03-27 | Pfizer | Derivados de dihidro-pirrolo-piridina |
| EP3668886A2 (en) | 2017-08-18 | 2020-06-24 | Adrx, Inc. | Tau aggregation peptide inhibitors |
| TWI801540B (zh) | 2018-03-23 | 2023-05-11 | 美商輝瑞大藥廠 | 哌嗪氮雜螺衍生物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6559140B2 (en) * | 2000-03-09 | 2003-05-06 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
| BRPI0507374A (pt) * | 2004-02-02 | 2007-07-10 | Pfizer Prod Inc | moduladores do receptor de histamina-3 |
| US8158673B2 (en) * | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| MX2010006162A (es) | 2007-12-07 | 2010-06-25 | Pfizer | Sal tosilato de una trans-n-isobutil-3-fluoro-3-[3-fluoro-4-(pirro lidin-1-il-metil)fenil]ciclobutanocarboxamida. |
-
2008
- 2008-01-10 WO PCT/IB2008/000088 patent/WO2008090429A1/en active Application Filing
- 2008-01-10 JP JP2009546829A patent/JP4585610B2/ja not_active Expired - Fee Related
- 2008-01-10 SI SI200830802T patent/SI2124933T1/sl unknown
- 2008-01-10 PT PT87022505T patent/PT2124933E/pt unknown
- 2008-01-10 BR BRPI0806473-3A patent/BRPI0806473A2/pt not_active IP Right Cessation
- 2008-01-10 KR KR1020097015310A patent/KR101108109B1/ko not_active IP Right Cessation
- 2008-01-10 NZ NZ577951A patent/NZ577951A/en not_active IP Right Cessation
- 2008-01-10 EP EP08702250A patent/EP2124933B1/en not_active Not-in-force
- 2008-01-10 RU RU2009124541/04A patent/RU2430099C2/ru not_active IP Right Cessation
- 2008-01-10 PL PL08702250T patent/PL2124933T3/pl unknown
- 2008-01-10 AU AU2008208653A patent/AU2008208653B2/en not_active Ceased
- 2008-01-10 CN CN2008800028688A patent/CN101631545B/zh not_active Expired - Fee Related
- 2008-01-10 DK DK08702250.5T patent/DK2124933T3/da active
- 2008-01-10 ES ES08702250T patent/ES2395744T3/es active Active
- 2008-01-10 MX MX2009007782A patent/MX2009007782A/es active IP Right Grant
- 2008-01-10 CA CA2676456A patent/CA2676456C/en not_active Expired - Fee Related
- 2008-01-18 AR ARP080100236A patent/AR064963A1/es unknown
- 2008-01-18 US US12/016,521 patent/US8314139B2/en not_active Expired - Fee Related
- 2008-01-21 UY UY030878A patent/UY30878A1/es not_active Application Discontinuation
- 2008-01-21 PE PE2008000164A patent/PE20081690A1/es not_active Application Discontinuation
- 2008-01-21 TW TW097102227A patent/TWI358294B/zh not_active IP Right Cessation
- 2008-01-22 CL CL200800180A patent/CL2008000180A1/es unknown
-
2009
- 2009-06-25 IL IL199587A patent/IL199587A/en not_active IP Right Cessation
- 2009-08-21 ZA ZA200905827A patent/ZA200905827B/xx unknown
-
2010
- 2010-03-19 HK HK10102903.0A patent/HK1137660A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY30878A1 (es) | La sal tosilato de trans-n-etil-3-fluoro-3-[3-fluoro-4 (pirrolidin-1-ilmetil)fenil] ciclobutanocarboxamida, composición farmacéutica conteniéndola y aplicaciones | |
| DE602006018301D1 (de) | Histamin-3-rezeptorantagonisten | |
| NO20082264L (no) | Histamin-3 reseptorantagonister | |
| WO2007105053A3 (en) | Tetralines antagonists of the h-3 receptor | |
| WO2007088450A3 (en) | Chromane antagonist of the h-3 receptor | |
| WO2007063385A3 (en) | Spirocyclic amine histamine-3 receptor antagonists | |
| MX2012007409A (es) | Derivados de benzamida sustituidos. | |
| BRPI0507374A (pt) | moduladores do receptor de histamina-3 | |
| JP2009161554A5 (es) | ||
| BRPI0513486A (pt) | derivados de cicloamino 1,3 substituìdo e seu emprego como antagonistas de receptor de histamina-3 | |
| EA201290519A1 (ru) | Положительные аллостерические модуляторы рецептора хинолин амида m1 | |
| DE502005010170D1 (de) | Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel | |
| BRPI0516079A (pt) | antagonistas de receptor de histamina-3 | |
| AR069611A1 (es) | Sal tosilato de un compuesto terapeutico y composiciones farmaceuticas de la misma | |
| BRPI0514820A (pt) | antagonistas de receptor de histamina-3 amina azabicìclicos | |
| BRPI0512567A (pt) | compostos antagonistas de receptor de histamina-3 diazabicìclico e respectivas composições farmacêuticas | |
| JP2009161517A5 (es) | ||
| CY1113762T1 (el) | Τοσυλικο αλας μιας θεραπευτικης ενωσης και φαρμακευτικες συνθεσεις αυτου | |
| CY1114789T1 (el) | Ανταγωνιστες υποδοχεα ισταμινης-3 | |
| EA201070336A1 (ru) | Ингаляционный азтреонам лизин для лечения нарушений, снижающих качество жизни, обусловленное состоянием здоровья при заболеваниях легких | |
| EA200970672A1 (ru) | Соединения с комбинацией каннабиноид-свантагонизма и ингибирования обратного захвата серотонина | |
| Machno et al. | APPLICATION OF LARYNGEAL MASK IN PATIENTS WITH ANKYLOSING SPONDILYTIS | |
| TH137272B (th) | ตัวควบคุมอัลโลเสตอริคแบบบวกของควิโนลีน เอไมด์ m1 รีเซพเตอร์ (quinoline amide m1 receptor positive allosteric modulators) | |
| CU20070070A7 (es) | Composición farmacéutica de agomelatina | |
| SM200900044A (it) | Dispositivo medicale per l'aspirazione del muco nasale. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20170908 |